Progress in respiratory virus vaccine development - Wikidata - wikimedia - TriplyDB

Progress in respiratory virus vaccine development

Progress in respiratory virus vaccine development

http://www.wikidata.org/entity/Q56894869

about

Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis Recent vaccine development for human metapneumovirus The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract.Antiviral B cell and T cell immunity in the lungs.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.Targeting RSV with vaccines and small molecule drugs.Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.Recent developments with live-attenuated recombinant paramyxovirus vaccines.A review of cost-effectiveness of palivizumab for respiratory syncytial virus.Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein.

P2860

Q26823449-FABD90BB-8D9A-4287-AD17-EB0AE7D1ADAD Q27023742-AC2BC998-B051-4B8E-AC43-629768FCF4BD Q30235334-7C70E3D0-256C-4815-9100-4B162629D074 Q34454614-B15138E4-469E-415E-9CBE-F9647149A275 Q35690781-1D0CBFAB-CA35-4A79-B49E-33CE51C45F06 Q36174346-7B6BA707-EF54-4185-9D7E-B490239E269B Q36607430-1B87C071-11C9-43F4-A305-7CD97E86DDCF Q37328584-88536B39-2BD4-46BE-B6AB-7D18F3A14324 Q37342874-B9A12078-95A8-40DB-BE87-F57492EDA961 Q37470206-4D3D86F6-7BFA-4B3A-AC22-C161A08F40F5 Q38008607-C3561BA0-04B6-4891-886B-20D95AA013D3 Q38058838-1519AD03-76B8-4B2E-9E12-60556E4EC3EF Q38176884-1DEB9579-D1F1-4C9E-847A-0EE3FF7F10C8

P2860

Progress in respiratory virus vaccine development

http://www.wikidata.org/entity/Q56894869

description

article

@en

im August 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2011

@uk

name

Progress in respiratory virus vaccine development

@en

Progress in respiratory virus vaccine development

@nl

type

label

Progress in respiratory virus vaccine development

@en

Progress in respiratory virus vaccine development

@nl

prefLabel

Progress in respiratory virus vaccine development

@en

Progress in respiratory virus vaccine development

@nl

P1433

Q56894869-71714020-EDD8-4E36-856A-5321B8AD95CB

P1476

Q56894869-E30B5487-E137-46C5-97A9-4B013D26EC49

P2093

Q56894869-A4565B47-D1EE-4870-A6AC-2F5660FFD150

P2860

Q56894869-02148027-3AD2-47CE-9723-001FA79B4522

Q56894869-0270A557-86AF-4DC3-A442-682176786D4C

Q56894869-0512F405-DD93-4598-9C64-06B5FEC59AB7

Q56894869-052E6DD7-E7E4-461F-8BDF-9F49664B604C

Q56894869-06E06D35-8B12-4A3F-B0F1-F87C8F4575AD

Q56894869-09556874-C3B0-4DC4-9F31-C30424B21E5F

Q56894869-0D392CC8-D0FD-4AD4-B004-64169D3027FE

Q56894869-1281BB1D-2ADA-4999-B6F3-479FF366F63E

Q56894869-1549D851-31C8-47BC-B892-0011F0B9025B

Q56894869-15DF5CC0-A834-4631-B2A9-240727AA4FA1

P304

Q56894869-5D4E89F9-2B1F-41BF-8A75-355E93DD8A45

P31

Q56894869-21F5940E-5835-4ADB-8D98-3EE60909DCF7

P356

Q56894869-E87BE6DA-8381-40EB-A029-D5FFCE4C13DC

P407

Q56894869-F9E2958E-16F9-49BC-AB68-F9ADD8627CF4

P433

Q56894869-A4D0A5FD-71CB-4ED5-BC9B-21FCA542E88F

P478

Q56894869-4FC7C474-7025-4FF9-BD8C-D3019AD894F4

P577

Q56894869-428B9225-22C0-4B74-B922-26C818DA2B9C

P698

Q56894869-612327B8-F952-4FB1-BC2A-13B17A1DE14C

P932

Q56894869-8D3A6D36-34F6-47E0-AA4C-BFC8A269ED46

P356

P1433

Seminars in Respiratory and Critical Care Medicine

P1476

Progress in respiratory virus vaccine development

@en

P2093

Alexander C Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

Distribution of airborne influenza virus and respiratory syncytial virus in an urgent care medical clinic

Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization

Genetic susceptibility to respiratory syncytial virus bronchiolitis in preterm children is associated with airway remodeling genes and innate immune genes

Global, regional, and national causes of child mortality in 2008: a systematic analysis

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

Respiratory syncytial virus and human bronchial epithelium.

RNA viruses in community-acquired childhood pneumonia in semi-urban Nepal; a cross-sectional study.

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

P304

527-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0031-1283289

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21858754

http://www.w3.org/2001/XMLSchema#string

P932

4547785

http://www.w3.org/2001/XMLSchema#string